Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALIRINOX in Resectable Pancreatic Cancer
NCT04010552Phase 2Unknown
- Sponsor
- Fundación de Investigación HM Hospitales
- Start
- May 2019
- Primary completion
- Aug 2023
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nanoliposomal irinotecan in pancreatic ductal adenocarcinoma (PDAC), sponsored by Fundación de Investigación HM Hospitales. Status: unknown.
02
Drugs
nanoliposomal irinotecan
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04010552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04010552.